Fluorophores are potentially useful for in vivo cancer diagnosis. Using relatively inexpensive and portable equipment, optical imaging with fl uorophores permits real-time detection of cancer. However, fl uorophores can be toxic and must be investigated before they can be administered safely to patients. A review of published literature on the toxicity of 19 widely used fl uorophores was conducted by searching 26 comprehensive biomedical and chemical literature databases and analyzing the retrieved material. These fl uorophores included Alexa Fluor 488 and 514, BODIPY FL, BODIPY R6G, Cy 5.5, Cy 7, cypate, fl uorescein, indocyanine green, Oregon green, 8-phenyl BODIPY, rhodamine 110, rhodamine 6G, rhodamine X, rhodol, TAMRA, Texas red, and Tokyo green. Information regarding cytotoxicity, tissue toxicity, in vivo toxicity, and mutagenicity was included. Considerable toxicity-related information was available for the Food and Drug Administration (FDA)-approved compounds indocyanine green and fl uorescein, but published information on many of the non-FDA-approved fl uorophores was limited. The information located was encouraging because the amounts of fl uorophore used in molecular imaging probes are typically much lower than the toxic doses described in the literature. Ultimately, the most effective and appropriate probes for use in patients will be determined by their fl uorescent characteristics and the safety of the conjugates.
when human toxicity is fi rst investigated in a phase I trial. We undertook an exhaustive search of the biomedical, chemical, and toxicology literature for information on 19 fl uorophores currently used in molecular imaging probes. The probes chosen were fl uorophores we had fi rsthand experience with or judged to be popular in the molecular imaging community. Focusing on doses resulting in adverse effects and the mechanisms of toxicity, we sought to determine the extent of available published toxicologic data.
Methods
Literature searches were performed for information on 19 organic fl uorophores ( Figure 1) ( Table 1 ) using multiple online database retrieval systems ( PubMed , EMBASE , TOXNET , Scopus , Biological Abstracts , Web of Science ) without restrictions on year published, with coverage extending back to 1900 ( Table 2 ). These six primary databases were searched by the two fi rst authors. Additional searching was performed in up to 20 other databases ( ChemIDplus , Merck Index records, TOXCENTER , HCAPLUS , CABA , BIOSIS , LIFESCI , PASCAL , RTECS , SciSEARCH , Aquire , BIOTECHABS , CSNB , DISSABS , EMBAL , ESBIOBASE , HEALSAFE , HSDB , MSDS-OHS , and ULIDAT ) by the third author because many of these additional, more specifi c databases had restricted access and required knowledge of a specialized query language ( Table 3 ) .
O PTICAL IMAGING has great potential as a clinical tool for cancer diagnosis. The most common optical molecular imaging probes are composed of fl uorescent dyes conjugated to targeting ligands, which have affi nity for tumor cells. When excited by a particular wavelength, fl uorophores emit light at a slightly longer wavelength (ie, the Stokes shift), thus differentiating the targeted, cancerous cells from adjacent normal tissue. Fluorophore conjugates can assist in detecting tumors submillimeter in size in real time, using portable and relatively inexpensive equipment. However, fl uorophores are also potentially toxic. To bring a new agent to clinical trials requires the preclinical assessment of an agent's toxicity in multiple species, to guide the determination of a dose at which there are no observed adverse effects. These data are relied heavily upon by the Food and Drug Administration (FDA) The general search method in the primary databases was to construct queries seeking the name of the fl uorophore or any alternate names in the title, abstract or indexing terms, and one of the following terms anywhere in the database record: toxicity or toxic* (wildcard), safety, or biocompatibility. Also, the fl uorophores Tokyo green, TAMRA, cypate, Cy 7, Alexa Fluor 488, and Alexa Fluor 514 were searched without accompanying toxicity-related words to maximize retrieval. This was deemed potentially benefi cial because little formal toxicity-related information is available for these compounds. When available, Chemical Abstracts Registry Numbers (CASRNs) were also searched, as well as names in databases with appropriate indexing, such as CAPlus . Furthermore, the initial developers and/or company producing each fl uorophore were contacted to request confi rmatory data as well as any fl uorophore toxicity information of note.
The titles and abstracts retrieved by each of the searches and the Material Safety Data Sheets provided by the manufacturer were reviewed for citations to potentially relevant articles. Relevant articles were selected, and the full text was obtained and examined. These publications were analyzed to obtain information on fluorophore dosage, mechanism of toxicity, and effect on an animal, human, or cellular system. This information was also analyzed to determine known toxic effects and doses and what further toxicity information must be known before the fluorescent compounds can be considered for human use.
Results
For all 19 fl uorophores, more than 21,288 articles (including duplicate items, which were returned more than once from separate databases) were returned in the searches. Of these, approximately 240 were selected for detailed analysis; a subset of these provided the relevant information that is cited in this literature review. The toxicologic data collected for each of the fl uorophores is summarized in the following sections. Evidence of cytotoxicity, tissue toxicity, in vivo toxicity, and mutagenicity is included. For some fl uorophores, additional toxicity information was available, including median lethal dose (LD 50 ) (or clinical symptom thresholds, which is used in more recent articles); mutagenicity (alters genetic structure); carcinogenicity (potentially induces cancer); teratogenicity (toxic to fetuses); and developmental toxicity. Although the determination of the toxicity of an individual fl uorophore is the investigational goal of this study, many of the fl uorophores have been investigated only when conjugated to another substance. We do report on the safety and toxicity of those conjugates. Nonhuman species toxicity data are included as many of the fl uorophores have not undergone human trials. Concentrations are reported in mg/mL or µg/mL for consistency; the results below are reported in order of decreasing amounts of information retrieved.
Indocyanine Green
Indocyanine green (ICG) was approved by the FDA in 1959 as a contrast agent for retinal angiography. Commercial names include Cardio Green, IC-Green, and Fox Green. ICG toxicity in cells, tissues, animals, and humans is well studied. Specifi c information on the mutagenicity of ICG, however, could not be located.
Although safe at clinical doses, at a concentration of 2.5 mg/mL, ICG has cytotoxic effects in vitro. 1 It accumulates intracellularly and decreases dehydrogenase activity in the mitochondria. [2] [3] [4] In liver cells, ICG inhibits mitochondrial oxygen consumption. 5, 6 In MIO-M1 cultured human retinal glial cells, 2.5 mg/mL ICG induced apoptosis through both reduction of thymidine incorporation in the MIO-M1 cultured human retinal glial cells and induction of the caspase cascade. 7 An ICG solution of 5 mg/mL is toxic to cultured lens epithelial cells. 8 ICG at a concentration of 0.25 mg/mL in cultured human retinal pigment epithelial (RPE) cells, ARPE19, exposed to light of wavelength 400 to 800 nm for 15 minutes, causes the upregulation of the cell-cycle arrest protein p21 as well as cell-cycle arrest genes bax and p53 . 9 ICG has photodynamic toxicities on the inner retina when exposed to light. 8, 10 It increases the rate of deoxyribonucleic acid (DNA) synthesis, and the toxicity increases with the duration of light exposure. 4 A 0.1 mL dose of ICG at a concentration of 2.5 mg/mL in rabbit eyes causes the loss of photoreceptor outer segments after 10 minutes of endoillumination. 11 The toxicity of ICG is enhanced by the presence of sodium. 12 Photodynamic toxicity has also been attributed to the production of a low level of reactive oxygen species 13 and has been investigated for use in laser-induced photodynamic therapy against infectious agents 14, 15 and cancerous cells. 16 The intravenous LD 50 for mice and rats ranges from 50 to 80 mg/kg and 60 to 87 mg/kg, respectively. 8, [17] [18] [19] The intravenous LD 50 for rabbits is 300 mg/kg. 19 The typical clinical dose of ICG is 3.572 µg/kg, and the maximum intravenous dose for humans is 5 mg/kg; thus, the clinical dose is approximately 4 log lower than the lowest LD 50 . 8 Because of its long history of use, there is extensive literature on the toxicity of ICG in humans. ICG is used during retinal surgery at the clinical concentration of 1.25 mg/mL in volumes of about 0.2 mL. 20 However, after intravitreous injection, ICG binds to plasma proteins, which accumulate at 1. the vitreoretinal interface. 21 ICG can cause functional damage and RPE atrophy at 10.0 mg/mL and 5.0 mg/mL concentrations when 0.05 mL is injected into the eye. 5, 22, 23 When ICG leaks through a macular hole into the subretinal space, it causes RPE atrophy at that site. 24, 25 ICG has been shown to induce apoptosis in RPE cells, as well as gene expression alterations and separation of the inner retina from the internal limiting membrane. 26 ICG is also damaging to glial cells. 27 It injures the nerve fi bers at the optic nerve head and can disrupt the activity of myelinated dorsal root axons in rats at a concentration of 0.22 mg/mL in the bloodstream. 28 Studies suggest that ICG should not be used during macular surgery because of its toxicity to the retina, and there is signifi cantly worse visual acuity in groups of patients in which ICG was used to visualize the retina. 20, 29 Furthermore, if accidentally splashed, ICG is diffi cult to rinse out of the eye, and if left in the subretinal space for more than 6 months, ICG can cause RPE atrophy, photoreceptor apoptosis, glial and ganglion cell death, and visual fi eld loss results. 27, 30 Idiosyncratic adverse reactions owing to ICG injection at the recommended dose include low blood pressure, itchiness, and pain in the vein. 18, 31 There have been at least two reported deaths owing to ICG injection resulting from anaphylactic reactions and cardiorespiratory arrest, and the estimated death rate is 0.0003%. 18 ICG does not appear to cross the blood-brain barrier and is excreted unmetabolized by the liver. 18, 32 Intravenous ICG rapidly binds plasma proteins, leading to prolonged clearance times in vivo.
In summary, ICG is a widely used, FDA-approved fl uorescent dye that at much higher doses than used clinically causes in vitro and in vivo toxicity.
Fluorescein
Fluorescein was FDA approved in 1976 as a contrast agent for angiography. Commercial names include Funduscein-25 and Fluorescite. Research regarding fl uorescein toxicity to tissues and in vivo is available, but information on the cytotoxicity and mutagenicity was lacking in the literature.
In excised embryonic chicken retina, a concentration of 0.2 mg/mL fl uorescein inhibits neuron growth. 33 Fluorescein may irritate the nerve roots when injected intrathecally (within the spinal cord) and affects the central nervous system. 34, 35 It is also known to cause ataxia (gait disturbance) in rats at a concentration of 4,200 mg/kg. 36 The median lethal concentration (LC 50 ) for turbot fi sh ( Scophthalmus maximus ) is 997.1 mg/L for 1 to 4 days of exposure. 35 The oral and intravenous LD 50 for mice is 4,738 mg/kg and 2,200 mg/kg, respectively. [36] [37] [38] [39] [40] The oral and intravenous LD 50 for rats is 6,721 mg/kg and 600 to 1,000 mg/kg, respectively. 36, 37, 39, 40 The intravenous LD 50 for dogs is 1,000 mg/kg. 37 The oral and intravenous LD 50 for rabbits is 2,500 mg/kg and 300 mg/kg, respectively. 39 The typical clinical dose ranges from 7.1 to 10 mg/kg, with 30 mg/kg used for the examination of the anterior segment of the eye. 37, 39, 41 Fluorescein may be a developmental toxin. Fluorescein has been shown to cross the placenta in rats and humans, and in one review of fl uorescein angiography performed in pregnant patients, a number of low birthweight babies were reported. 42 The study, however, was not controlled for other risk factors.
Adverse reactions to intravenous fl uorescein occur in 4.82% of patients. 43 Of patients with reactions, nausea and vomiting are the most common (10-20% and 1.78%, respectively). 43, 44 Patients also experience dizziness, headache, diarrhea, convulsions with bradycardia, circulatory problems, irritation at the injection site, vasovagal episodes (fainting), pruritus (itchy), urticaria (in 0.5% of patients with reactions), myocardial infarction, breathlessness, extravasation, thrombophlebitis (infl ammation of a clot in the superfi cial venous system), local tissue necrosis, laryngeal and facial edema, bronchospasm, and anaphylaxis and allergic reactions (in 0.5-1% of total patients). [43] [44] [45] [46] [47] [48] The primary route of excretion is the kidney. 38 Cardiac arrest and death are very rare; the mortality rate is 0.0005%. 18, 46 Fluorescein is a widely used, FDA-approved fl uorescent dye. Based on the existing data, it can have toxic effects in cell culture and on patients at high doses.
Rhodamine 6G
Rhodamine 6G (Rh6G) is a non-FDA-approved fl uorophore that has demonstrated mutagenicity and toxicity in cells, tissues, and organisms. Rh6G is cytotoxic to Friend leukemia cells and doxorubicin-resistant variant cells, ARN15, in culture, killing 100% of the former at a dose of 0.1 µg/mL and the latter at 10 µg/mL. 49 Rh6G is also lethal to Salmonella TA98 and TA100 at 3.0 mg/plate and 0.5 mg/plate, respectively. 50 Rh6G demonstrates toxicity to tissue, causing severe damage to rat retinal ganglion cells at a dose of 2 µL at 5.0 mg/mL concentration. 51 In mice, Rh6G accumulates in mitochondria and disrupts oxidative phosphorylation and adenosine triphosphate (ATP) synthesis by inhibiting the function of adenosine triphosphatase (ATPase) and the processing of the mitochondrial matrix peptides. 52 At an intravenous dose of 0.5 mg/kg/d for 4 days, ATP synthesis in pregnant mice was reduced by almost half. At a concentration of 10 µg dye/mg protein, 86% of ATPase production in the mice was inhibited. 53 Studies suggest that Rh6G is a mutagen at high concentrations. It induces single-strand breaks in the DNA of Chinese hamster ovary cells at concentrations of 500 to 1,000 µg/plate and is mutagenic to Salmonella strains. 54 Studies also suggest that Rh6G may be a carcinogen. In one study, it potentially caused integumentary keratoacanthomas, pheochromocytomas, and malignant pheochromocytomas in rats that were fed 10 or 12 mg/kg of Rh6G for at least 14 days. 55 Rh6G has demonstrated teratogenic effects in mice as well. 56 Of pregnant mice injected intraperitoneally with 15 mg/kg/d of Rh6G, 61% experienced gross malformations of the fetus. This study also suggests developmental toxicity of Rh6G as 17% of the mice fetuses experienced prenatal mortality and the typical fetal body weight was signifi cantly reduced. 52 Thus, Rh6G is a contrast agent that has demonstrated a host of toxic effects to cells, tissues, and organisms at high doses.
Texas Red
Information on the cytotoxicity, tissue toxicity, in vivo toxicity, and mutagenicity of Texas red is limited. Although studies on the toxicity of pure Texas red were not returned in any search, information on Texas red conjugates was available. When Texas red is conjugated to bovine serum albumin (BSA), it alters the protein's physicochemical characteristics. 57 It causes a minimal yet signifi cant change on the relative charge of BSA but does not infl uence the size or isoelectric point of the protein. 57 Conjugates of Texas red have shown phototoxic effects in rat erythrocytes exposed to epi-illumination. Of the four BSA-fl uorophore conjugates tested in these cells (fl uorescein isothiocyanate [FITC], tetramethylrhodamine isothiocyanate [TRITC], BODIPY-FL, and Texas red), Texas red is the third most phototoxic, ranking below FITC and BODIPY-FL. 58 In lamprey larvae, normal brain neuron regeneration when labeled with 62.5 mg/mL Texas red dextran amine, shows no neurotoxic effects. 59 
BODIPY FL (Boron-Dipyrromethene)
A BODIPY-verapamil conjugate is toxic to multidrug resistant human KB carcinoma cell lines in culture at concentrations greater than 10 µM (approximately 7.3 µg/mL) and is more toxic than verapamil alone. 60 Another derivative of the BODIPY fl uorophore, C11-BODIPY 581/591 (4,4-difl uoro-5-(4-phenyl-1,3-butadienyl)-4-bora-3a,4a-diaza-s -indacene-3-undecanoic acid), an oxidation-sensitive fl uorescent lipid peroxidation probe, is not toxic to rat-1 fi broblasts in culture at concentrations up to 50 µM (approximately 0.03 mg/mL), highest concentration tested. 61
Cy5.5
The only information located regarding the in vivo toxicity of Cy5.5 is given on the Material Safety Data Sheet; it is harmful if swallowed and may cause allergic respiratory and skin reactions. 62 A study of Cy5.5 conjugated with the caspase-cleavable peptide DEVD, Cy 5.5-DEVD26-PEI-DOCA 20 , found that the compound is not cytotoxic to HeLa cells at concentrations of 20 µg/mL or less. 62
Cypate
Bioconjugates of cypate are not toxic to animals up to 10 µmol/kg, and Cyp-GRD (cypate conjugated with a linear hexapeptide, GRDSPK) is not toxic to the α v β 3 -integrin (ABI)-positive tumor cell line, A549, in culture up to a concentration of 100 µM (approximately 0.1 mg/mL). 63, 64 In general, cypate is considered a "biocompatible" dye. 65
Rhodamine 110
Limited toxicity information is available for rhodamine 110, also commonly known as rhodamine green. Rh110 accumulates in the mitochondria in human lymphoblastoid cells but shows no cytotoxic effects at concentrations up to 10 µM (approximately 5.1 µg/mL). 66 However, it has been found cytotoxic at concentrations greater than 100 µM (approximately 51 µg/mL) and accumulates in Friend leukemia cells, causing cell death. 49 
Oregon Green
Information on the cytotoxicity, toxicity to tissues, in vivo toxicity, and mutagenicity of Oregon green is limited. In one experiment, 10 µM (approximately 5.1 µg/mL) Oregon green 488 conjugated with paclitaxel was safely injected intravenously into swine, which were observed for up to 96 hours postinjection and suffered no toxicity-related effects. 67
Tokyo Green
The Tokyo green dyes are an array of recently developed fl uorescein derivatives. 68 Information on the tissue toxicity, in vivo toxicity, and mutagenicity of Tokyo green is limited. The toxicity profi le of Tokyo green is generally safe and similar to that of fl uorescein (unpublished data by Yasuteru Urano, PhD, of University of Tokyo, 2007).
Remaining Dyes Searched
For Alexa Fluor 488, Alexa Fluor 514, BODIPY R6G, Cy7, carboxyrhodamine 6G, 8-phenyl BODIPY, rhodamine X, rhodol, and 6-TAMRA (tetramethyl-6-carboxyrhodamine), no toxicity-related information was returned in any search.
Discussion
Molecular imaging is emerging as a powerful diagnostic tool for cancer. Among the modalities capable of molecular imaging, optical imaging holds great promise for clinical translation and has the advantages of low cost, real-time acquisition, and portability. Optical imaging often uses fl uorophores with characteristic emission spectra linked to targeting ligands. Using multiple fl uorophores can open possibilities for multiplex imaging (imaging multiple targets simultaneously). However, if fl uorophores are to be used in patients, their potential toxicities must fi rst be investigated.
Recognizing that fl uorophore conjugates may have different toxicity profi les compared with unbound fl uorophores, we reviewed the published information on the toxicity of 19 commonly used fl uorophores to survey the current state of knowledge.
The databases were selected based on their content coverage and availability. PubMed , EMBASE , TOXNET , Scopus , Biological Abstracts , Web of Science , ChemIDplus , Merck Index records, TOXCENTER , HCAPLUS , CABA , BIOSIS , LIFESCI , PASCAL , RTECS , SciSEARCH , Aquire , BIOTECHABS , CSNB , DISSABS , EMBAL , ESBIOBASE , HEALSAFE , HSDB , MSDS-OHS , and ULIDAT were all searched for articles containing fl uorophore toxicity data. 69, 70 The fi rst six databases cite over 60 million articles and draw references from a broad range of relevant subject areas, including toxicology, human medicine, biomedical science, life science, chemistry, hazardous substances, and environmental health. The remaining 20 databases, available from Chemical Abstracts Service/ Science Technology Network (CAS/STN ) , can be searched using a sophisticated command-based query system; many have additional indexing, are more highly targeted, and can return more specifi c articles from unique journals and resources that may not have been covered by the six main databases. The combination of these databases facilitated a comprehensive examination of published toxicity information. Approximately 20% of articles were returned multiple times, in each of several separate databases, indicating subject overlap between the databases. However, some searches returned no toxicity-related data. This strongly suggests that there are no published results for toxicity studies conducted on these fl uorophores.
The doses of fl uorophore or fl uorophore-conjugate used in animals and patients are considerably lower than the toxic doses described in the studies we reviewed. For example, a typical clinical dose of ICG is approximately 3.6 µg/kg, whereas the LD 50 for mice and rats ranges from 50 to 87 mg/kg, a safety factor of 10 4 . Likewise, the typical clinical dose of fl uorescein is about 7.1 mg/kg for a 70 kg human, whereas the LD 50 for mice and rats ranges from 300 to more than 2,000 mg/kg. These are comparable to other commonly used clinically approved contrast agents such as gadolinium-diethylenetiramine pentaacetic acid (Gd-DTPA) for magnetic magnetic imaging and isopamidol for computed tomography, both of which have dose to LD 50 safety factors of approximately 1/100. 71, 72 Thus, the "therapeutic index" is large enough to allow for the clinical use of ICG and fl uorescein despite their toxic effects at higher doses. Molecular imaging probes may also be administered topically rather than systemically, further lowering the potentially toxic dose and increasing the therapeutic index. Determining the safe dose of the majority of these fl uorophores, however, will require further clinical and laboratory investigation.
There were diffi culties in performing these searches. One major hurdle was the lack of a CASRN for some of the fl uorophores in their unconjugated forms, although many fl uorophores had multiple CASRNs for multiple forms with distinct conjugation groups. Clear CASRN identifi cation helps ensure that the appropriate compound is being searched and investigated in some of the databases, particularly those databases from STN , such as CAPlus . It is possible that some potentially useful articles could have been missed owing to problematic CASRN identifi cation. Other diffi culties encountered were the formatting of the names or search terms as various formats often produced varied results (eg, Cy5.5 vs cy 5.5) and including as many colloquial or trade names for a fl uorophore as possible (such as rhodamine 6G, which is also called basic red 1 and basic rhodamine yellow). There was some ambiguity involved with some of these trade names. For example, rhodol refers to a nonfl uorescent compound, p-methylaminophenol sulfate, as well as the fl uorophore listed here. There is extensive toxiciology literature on p-methylaminophenol sulfate because it is often used in the cosmetics industry, so it was particularly important to verify the actual compound involved. As many relevant CASRNs and other search terms as possible were included for each fl uorophore. Furthermore, to ensure the validity of our search results and to avoid publication bias, the inventors and companies marketing the fl uorophores searched were contacted, and their contributions were included.
We have described the known published toxicity of candidate fl uorophores for molecular imaging probes. What emerges is the patchwork of information that is publicly available. No standardized toxicity panels have been published for even the major fl uorophores. However, in molecular imaging compounds, the fl uorophores are conjugated to targeting ligands, which bind to tumor cells in vivo. It is recognized that once a fl uorophore is chemically changed in any way, such as conjugating it to a targeting ligand, its toxicity is likely to change. Also, the exact chemical or energetic form of the fl uorophore could contribute to its toxicity, for example, the light-activated form of ICG. However, we further recognize that after the compound is metabolized in the body, the pure fl uorophore may be released and its own inherent toxicity again becomes relevant.
The current information on the toxicity of these fl uorophores is not complete. Although suffi cient data regarding the toxicity of the FDA-approved agents ICG and fl uorescein are available, there is very little published information on many of the unapproved fl uorophores. Many of the experiments described in articles we reviewed concerned toxicity studies of other compounds in which the fl uorophore was used as part of a biomarker system. Thus, it was impossible to differentiate the toxicity of the experimental agent from that of the fl uorophore. Further toxicity studies of the fl uorophores for which there are few data are needed. However, the experience with ICG and fl uorescein is encouraging because of the large therapeutic index for these agents and the low doses typically required of molecular imaging probes. Ultimately, the most effective and appropriate probes for use in patients will be determined based on their tissue penetration, specifi city, effi ciency, fl uorescent persistence, and safety.
Conclusion
In this literature review, the published information regarding the toxicity of fl uorophores used in molecular imaging probes is described. We found that there was substantial inconsistency in the amount of toxicity data among the fl uorophores investigated. However, in those fl uorophores for which there was adequate information, there is room for optimism that the dose used for clinical probes will be substantially lower than the doses associated with toxicity. Further research into the toxicity of these compounds is needed to bring the diversity of available fl uorophores to the clinic.
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